PASCA program study after stem cell transplant for myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study checks whether the PASCA health program helps reduce complications in people with multiple myeloma after their first stem cell transplant. It may help by improving how patients manage side effects during recovery and ongoing treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have symptomatic multiple myeloma and are eligible for your first autologous stem cell transplant
- Before the transplant, your disease response was complete response, very good complete response, or partial response
- You can fully take part for the entire study and be followed regularly (medical, social, and practical follow-up)
- You are able to communicate in French and understand and sign consent
- You live in the Auvergne-Rhône-Alpes region or in the Saône-et-Loire department
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a prehabilitation program using adapted physical activity can help multiple myeloma patients prepare for a stem cell transplant. It may improve your strength and recovery before and after the transplant.
This trial studies whether a structured exercise program before an autologous (your own cells) stem cell transplant can improve health and fitness in people with multiple myeloma. The goal is to safely prepare your body for transplant, and the study includes fitness testing and ongoing exercise training.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This Phase 2 study tests whether people with newly diagnosed multiple myeloma can safely delay or avoid an immediate stem cell transplant if they respond well to early treatment. It aims to see if this “response-adapted” approach can still control the disease while reducing the need for upfront transplant for some patients.
This trial tests an investigational drug for people with multiple myeloma that has returned after a stem cell transplant from a donor. It aims to see if the drug can help control the cancer when other treatments haven't worked.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.